AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02036307 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DHA-enriched
Description: DHA 3g + 600 mg EPA in 6 g of fish oil/day given for 4 weeks
Study NCT02036307 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EPA-enriched
Description: EPA 2.4 g + DHA 600mg in 6 g of fish oil/day for 4 weeks
Study NCT04498624 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: inverted flap
Description: full thickness macular hole surgery
Study NCT04498624 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: peeling internal limiting membrane (ILM)
Description: full thickness macular hole surgery
Study NCT03097770 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD19/20-CAR vector-transduced T cells
Description: genetically engineered lymphocyte therapy
Study NCT02549313 — intervention group
Intervention type: PROCEDURE
Intervention: position changes of the head
Description: Registration of blood flow changes induced when the patient's head will be tilted at 0 ° (that is to say flat), 15 ° and 30 ° (the order of actions will be determined by drawing lots). The patient will remain 10 minutes in each of these positions.
Study NCT00766298 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 16 week intervention; 6 exercise sessions weekly w 3 supervised exercise sessions weekly utilizing cycling or walking/jogging. Participants maintain exercise diaries: wks 1-4; 30 minutes at 60-70% MHR, wks 5-8; 40 minutes at 60-70% MHR, weeks 9-16; 40 minutes at 75% MHR
Study NCT00766298 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Loss
Description: The reduction of kcal/day through implementation of low fat diet
Study NCT00766298 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and weight loss
Description: Exercise: 16 week intervention; 6 exercise sessions weekly w 3 supervised exercise sessions weekly utilizing cycling or walking/jogging. Participants maintain exercise diaries: wks 1-4; 30 minutes at 60-70% MHR, wks 5-8; 40 minutes at 60-70% MHR, weeks 9-16; 40 minutes at 75% MHR.~Weight Loss: Reduction of kcal/day through implementation of a low fat diet.
Study NCT00566735 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Razadyne
Description: The starting dose of study medication is 4 mg twice a day
Study NCT00566735 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 mg, 2 times a day
Study NCT03980873 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ESTEEM (Effective Sikills to Empower Effective Men)
Description: ESTEEM (Effective Skills to Empower Effective Men) is a 10-session intervention based on the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (Barlow et al., 2010).~Is an individually-delivered cognitive behavioral treatment with efficacy for reducing stress-sensitive mental health disorders (e.g., depression, anxiety) by enhancing emotion regulation abilities; reducing maladaptive cognitive, affective, and behavioral avoidance patterns; and improving motivation and self-efficacy for enacting behavior change
Study NCT02164240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Intervention Description: 3 days of once daily sunitinib alternating with 4 days of once daily regorafenib throughout each 28 day cycle. The starting dose level (level 1) is sunitinib 37.5 mg/d and regorafenib 120 mg/d, and doses will be escalated in subsequent cohorts following a classical 3+3 design up to sunitinib 50 mg/d and regorafenib 160 mg/d or until maximum tolerable dosage (MTD) and recommended phase II dose (RP2D) is determined. Number of Cycles: until progression or unacceptable toxicity develops.
Study NCT02164240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Intervention Description: 3 days of once daily sunitinib alternating with 4 days of once daily regorafenib throughout each 28 day cycle. The starting dose level (level 1) is sunitinib 37.5 mg/d and regorafenib 120 mg/d, and doses will be escalated in subsequent cohorts following a classical 3+3 design up to sunitinib 50 mg/d and regorafenib 160 mg/d or until maximum tolerable dosage (MTD) and recommended phase II dose (RP2D) is determined. Number of Cycles: until progression or unacceptable toxicity develops.
Study NCT05959590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxides 11.2Mg Solution for Injection
Description: the drug will be injected at a single dose of up to 7 mg/Kg and MRI will be performed after 24 hrs.
Study NCT00964730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talampanel
Description: titrated to 50mg three times a day over 9 days and a single dose administered on Day 10
Study NCT00964730 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Moxifloxacin
Description: Placebo administered three times a day over 9 days and a single dose of moxifloxacin administered on Day 10
Study NCT00964730 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: administered three times a day over 9 days and a single dose administered on Day 10
Study NCT02001818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib, Pegylated interferon alpha-2b, Imatinib
Description: All patients joining the study will receive treatment with oral nilotinib at 300mg twice daily. This will be given as monotherapy for 3 months initially, prior to commencement of combination therapy with Pegylated interferon alpha-2b added to nilotinib. Patients intolerant of nilotinib will have the option of switching to imatinib.
Study NCT00955825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 300 IR
Description: 300 IR grass pollen allergen extract tablet taken daily for approximately 6 months starting 4 months before the grass pollen season and over the grass pollen season
Study NCT00955825 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo sublingual tablet taken daily for approximately 6 months starting 4 months before the grass pollen season and over the grass pollen season
Study NCT02751580 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: Attend a virtual visit via the JeffConnect telehealth app
Study NCT02751580 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03109223 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sole source nutrition
Description: Infant formula
Study NCT03109223 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sole source nutrition
Description: Infant formula
Study NCT01767714 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Granulocyte-colony stimulating factor (G-CSF)
Description: 10 µg/kg/day G-CSF, administered by subcutaneous (SC) injection
Study NCT01767714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte-colony stimulating factor (G-CSF)
Description: 10 µg/kg/day G-CSF, administered by subcutaneous (SC) injection
Study NCT01767714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: 0.24 mg/kg/day subcutaneous injection
Study NCT01566240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 80 mg/m2 (capped at 162mg maximum total dose) weekly for 6 weeks i.e. on days 1, 8, 15, 22, 29 \& 36.
Study NCT01566240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 2 (capped at 270mg maximum total dose) weekly for 6 weeks i.e. on day 1, 8, 15, 22, 29, \& 36.
Study NCT01566240 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Radiotherapy comprising external beam 40-50.4Gy in 20-28 fractions plus intracavity brachytherapy to achieve a minimum total EQD2 dose of 78-86Gy.
Study NCT01566240 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy comprising external beam 40-50.4Gy in 20-28 fractions plus intracavity brachytherapy to achieve a minimum total EQD2 dose of 78-86Gy.
Study NCT01767714 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.24mg/kg/day placebo (0.9% Sodium Chloride) administered by subcutaneous injection
Study NCT00609908 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Split skin graft
Description: After wound bed preparation the skin defect is covered with a skin transplant (split skin graft)
Study NCT00609908 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: skin stretching device
Description: after woundbed preparation the wound is primarily closed by aid of the skin stretching device
Study NCT00609908 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: serial excision
Description: as much scar as possible is excised, whereafter the wound is closed
Study NCT00609908 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: skin stretching device
Description: after the scar is excised, the wound is primarily closed by aid of the skin stretching device
Study NCT02726828 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intrathecal morphine
Description: patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 0.3 mg intrathecal morphine1 ml volume.
Study NCT02726828 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intrathecal ketamine
Description: patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 0.1 mg/kg intrathecal ketamine in 1ml volume.
Study NCT02726828 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intrathecal morphine + ketamine
Description: patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and intrathecal morphine + ketamine 0.3 mg and 0.1 mg/kg respectively in 1 ml volume.
Study NCT00941655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 460 mg/m\^2 diluted in 2.0 L/m\^2 of dextrose 5% in water (D5W) given as a heated intraperitoneal perfusion.~Systemic chemotherapy - Oxaliplatin 85 mg/m\^2 over 120 minutes,
Study NCT00941655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 165 mg/m\^2 IV over 90 minutes
Study NCT00941655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Surgery and heated intraperitoneal chemotherapy with Fluouracil (5-FU) 400 mg/m\^2 intravenous (IV) over 5 minutes.~systemic chemotherapy -3200 mg/m\^2 continuous intravenous over 48 hours.
Study NCT00941655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: surgery and heated intraperitoneal chemotherapy -20 mg/m\^2 intravenous over 5 minutes.~systemic chemotherapy - 200 mg/m\^2 intravenous over 120 minutes.
Study NCT00941655 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastrectomy and/or metastasectomy
Description: Gastrectomy: tumor resection and a bypass; palliative treatment for pain, bleeding, obstruction and/or if deemed in the best interest of the patient.~Metastasectomy: anatomical segmental resection to render the patient no evidence of disease (NED) with at least 1cm negative margins when possible, followed by systemic chemotherapy.
Study NCT01566240 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 40 mg/m2 (capped at 70mg total dose) weekly for five weeks maximum, commencing in the first week of radiotherapy or as soon as blood counts have recovered from induction chemotherapy.
Study NCT02745132 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Neuropsychological evaluation and Brain MRI
Description: This is a prospective study. The only intervention planned will consist of performing neuropsychological tests and cerebral MRI that will be carried out on a single group cohort at different times.~Notwithstanding, we will record the exposure to DAA to assess any change in neurocognitive function and MRI imaging.~Anti-HCV regimens will be used according to clinical practice as indicated into the current guidelines (1)~(1)European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015 Jul;63(1):199-236. doi: 10.1016/j.jhep.2015.03.025. Epub 2015 Apr 21. PubMed PMID: 25911336.
Study NCT04180800 — intervention group
Intervention type: OTHER
Intervention: Lubben Social Network Scale - 6
Description: One short oral interview to complete the Lubben Social Network Scale in auto-survey, translated in French. It contains 6 questions on 30 points, higher scores are associated with more social engagement, lower scores, specifically under 12/30, are associated with social isolation.
Study NCT01891760 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermagraft
Description: Dermagraft treatment regimen of one application applied topically to the ulcer, weekly, for a maximum of 8 weeks (8 application maximum).
Study NCT01891760 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Profore
Description: Four-layer compression bandaging therapy.
Study NCT03016546 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BEST-maCARE
Description: Features of the integrated BEST-maCARE intervention approach include: Integration of depression screening and linkages to HIV and mental health treatment in the context of perinatal care; A trained, clinic-based nurse (study nurse) plays a mediating role between the health system and its beneficiaries; scheduling of appointments; and, accompanying the patient as needed to initial appointments if desired, and, follow up. Low cost, mobile phone technology is used for frequent one:to:one patient contact with a health care provider (the study nurse) to facilitate continuity of care (for mental health, HIV and pregnancy across the continuum of care from prenatal through postpartum) and promotion of self-care (adherence) and retention in care with a theory-guided, empirically-supported, standardized counseling intervention that is delivered proactively by the study nurse over 18 weeks.
Study NCT03016546 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control Condition
Description: The control group will receive an intervention that is time and attention equivalent to the experimental condition. The attention effect that is likely with provision of a mobile phone in the experimental condition will be controlled by providing mobile phone to the control group participants and, they will receive time matched calls from the study nurse with content of the calls focused on infant and maternal nutritional health education per Indian National Guidelines. The phone will be used for delivery of the interventions and may also be used by study staff for purposes of establishing contact or to collect survey interview data if necessary. Time, date, and content of all phone contacts will be documented by the nurse and evaluated in the analysis.
Study NCT00004929 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MUC-2-KLH vaccine
Study NCT00004929 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QS21
Study NCT03885089 — intervention group
Intervention type: DRUG
Intervention: Infliximab [infliximab biosimilar 3]
Description: \<Psoriasis> The usual dose is 5 mg as Infliximab (Genetical Recombination) \[Infliximab Biosimilar 3\] for every kg of body weight given as an intravenous infusion. After an initial dose is given, the subsequent doses are given at Weeks 2 and 6, and every 8 weeks thereafter. After a dose at Week 6 is given, the dose may be increased or the dosing interval may be reduced for patients who have an incomplete response or reduced effects. These adjustments should be made in a stepwise manner according to condition of patients. The maximum dose is 10 mg for every kg of body weight at the dosing interval of 8 weeks and 6 mg for every kg of body weight at a reduced dosing interval. The minimum dosing interval is 4 weeks.
Study NCT02732340 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: triple-branched stent graft
Description: place the triple-branched stent graft into the aortic arch, descending aorta ,the left subclavian artery, the left common carotid artery, and the innominate artery.
Study NCT03694041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAD: APX-115
Description: Drug: APX-115 SAD APX-115 SAD for 1day
Study NCT03694041 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SAD: Placebo
Description: Drug: Placebo Placebo for 1day
Study NCT03694041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAD: APX-115
Description: Drug: APX-115 MAD APX-115 MAD repeatedly administered.
Study NCT03694041 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MAD: Placebo
Description: Matching study drug will be repeatedly administered.
Study NCT03694041 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Food effect: fasted and fed
Description: A single dose of APX-115, selected from the SAD study, will be administered under fasted and fed condition.
Study NCT03694041 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Metabolic probe with or without APX-115
Description: A metabolic probe will be administered with and without APX-115.
Study NCT03337152 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: primaquine
Description: Participants receive primaquine for 14 days at 0.5 mg/Kg. Drug administration will be directly observed.
Study NCT03337152 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: chloroquine + primaquine
Description: Participants will receive chloroquine for 3 days concomitant with primaquine for 14 days at 0.5 mg/Kg. Drug administration will be directly observed.
Study NCT00656734 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MDX 1411
Description: MDX-1411 (fully human monoclonal antibody) administered as an i.v. infusion for up to 5 doses per cycle, with a maximum of 17 cycles total
Study NCT02288065 — intervention group
Intervention type: DRUG
Intervention: sterile talc pleurodesis
Description: medical thoracoscopy and talc pleurodesis. No specific device is studied.
Study NCT00004992 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive lifestyle
Study NCT00004992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Study NCT00004992 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02612441 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real Acupuncture Needles
Description: Acupuncture needles
Study NCT02612441 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham Acupuncture Needles
Description: sham Acupuncture Needles
Study NCT03004469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P-3074
Study NCT03004469 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Finasteride
Study NCT03004469 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: P-3074 Vehicle
Study NCT03004469 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: P-3074 Vehicle
Study NCT03004469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finasteride Placebo
Study NCT03004469 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Finasteride Placebo
Study NCT03498287 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Study Device
Description: Real study device applied to affected wrist (or higher CTS severity wrist if patient has bilateral CTS) for 8-10 hours daily for 56 days (8 weeks).
Study NCT03498287 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Device
Description: Sham device applied to affected wrist (or higher CTS severity wrist if patient has bilateral CTS) for 8-10 hours daily for 56 days (8 weeks). \*Note: participants in the sham group are given the real study device at the end of the Post-Treatment/Follow-up Phase.
Study NCT02580994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion at the dose of 200 mg on day 1 every 3 weeks
Study NCT02580994 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cis/carboplatin and etoposide
Description: Cisplatin 80 mg/m2 or Carboplatin Area Under the Curve (AUC) 5 IV infusion on day 1 Etoposide 100 mg/m2 IV infusion on day 1, 2 and 3
Study NCT02580994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cis/carboplatin and etoposide
Description: Cisplatin 80 mg/m2 or Carboplatin Area Under the Curve (AUC) 5 IV infusion on day 1 Etoposide 100 mg/m2 IV infusion on day 1, 2 and 3
Study NCT02542436 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention administered in this study
Study NCT01566240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 40 mg/m2 (capped at 70mg total dose) weekly for five weeks maximum, commencing in the first week of radiotherapy or as soon as blood counts have recovered from induction chemotherapy.
Study NCT02229630 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pregnant women with intra-uterine growth restricted Foetuses
Description: Diffusion-weighted cerebral MRI before 32 weeks of gestation
Study NCT02757781 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community of Practice
Description: The intervention group will be offered participation for 12 months in a virtual CdP based on a web 2.0 platform. The control group will receive usual training.
Study NCT04408118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab (840 mg) will be administered intravenously on Days 1 and 15.~The first infusion of atezolizumab will be administered over 60 minutes. If the first infusion is tolerated, all subsequent infusions may be delivered over 30 minutes.